ARS Pharmaceuticals, Inc. (SPRY)

9.46 +0.13 (+1.39%) At close: 04:00PM EDT

ARS Pharmaceuticals, Inc.

11682 El Camino Real
Suite 120
San Diego, CA 92130
United States
858 771 9307
https://ars-pharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 24

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL	Founder, President, CEO & Director	2.75M	N/A	1966
Dr. Sarina Tanimoto M.B.A., M.D.	Co-Founder & Chief Medical Officer	2.47M	N/A	1969
Dr. Robert Bell Ph.D.	Co-Founder & Chief Science Officer	N/A	N/A	N/A
Ms. Kathleen D. Scott CPA	Chief Financial Officer	N/A	N/A	N/A
Mr. Brian T. Dorsey M.S.	Chief Operations Officer	N/A	N/A	1969
Mr. Justin Chakma	Chief Business Officer & Secretary	N/A	N/A	1990

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Corporate governance

ARS Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.